Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Johns Hopkins heart researchers develop formula to better calculate 'bad' cholesterol in patients

18.11.2013
Findings follow previous study showing that commonly used equation underestimates heart disease danger for many at high risk

Johns Hopkins researchers have developed a more accurate way to calculate low-density lipoprotein (LDL) cholesterol, the so-called "bad" form of blood fat that can lead to hardening of the arteries and increase the risk of heart attack and stroke.

If confirmed and adopted by medical laboratories that routinely calculate blood cholesterol for patients, the researchers say their formula would give patients and their doctors a much more accurate assessment of LDL cholesterol.

"The standard formula that has been used for decades to calculate LDL cholesterol often underestimates LDL where accuracy matters most — in the range considered desirable for patients at high risk for heart attack and stroke," says Seth S. Martin, M.D., a cardiology fellow at the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Martin is first author of the study detailed in a Nov. 19, 2013 article in the Journal of the American Medical Association.

Many studies have shown that higher levels of LDL cholesterol signal greater risk of plaque accumulating in heart arteries. Since 1972, a formula called the Friedewald equation has been used to gauge LDL cholesterol. It is an estimate rather than a direct measurement. However, physicians use the number to assess their patients' risk and determine the best course of treatment.

The Friedewald equation estimates LDL cholesterol with the following formula: total cholesterol minus HDL cholesterol minus triglycerides divided by five. The result is expressed in milligrams per deciliter. That equation, the researchers say, applies a one-size-fits-all factor of five to everyone; a more accurate formula would take specific details about a person's cholesterol and triglyceride levels into account.

Using a database of blood lipid samples from more than 1.3 million Americans that were directly measured with a traditional and widely accepted technique known as ultracentrifugation, the researchers developed an entirely different system and created a chart that uses 180 different factors to more accurately calculate LDL cholesterol and individualize the assessment for patients.

"We believe that this new system would provide a more accurate basis for decisions about treatment to prevent heart attack and stroke," says Martin.

Results of the new study are built on research by the same authors from the Johns Hopkins University School of Medicine and published in the Journal of the American College of Cardiology. In that study, the researchers compared samples assessed using the Friedewald equation with a direct calculation of the LDL cholesterol.

They found that in nearly one out of four samples in the "desirable" range for people with a higher heart disease risk, the Friedewald equation was not accurate.

"As a result, many people — especially those with high triglyceride levels — may have a false sense of assurance that their LDL cholesterol is at an ideal level. Instead, they may need more aggressive treatment to reduce their heart disease risk," says Steven Jones, M.D., director of inpatient cardiology at The Johns Hopkins Hospital and a faculty member at the Ciccarone Center who is the senior author of the study.

The lipid profiles used for the study were from a laboratory in Birmingham, Ala., which provides a detailed analysis of samples sent in by doctors across the country. Except for the age of people on whom the samples were based (59 years on average) and the gender (52 percent of the samples were from women), the patients were not identifiable to the researchers. That database was almost 3,000 times larger than the sample used to devise the Friedewald equation 43 years ago.

Jones, who originated the idea to use the large laboratory database to assess the Friedewald equation, says the information was provided by the lab at no cost. The lab, Atherotech, did not provide any funding for the research or input on the calculations or study article. The database used in the study is registered on the website http://www.clinicaltrials.gov and will be an important resource for ongoing scientific investigation.

Jones and Martin are listed on a patent pending for the new system, which was filed by The Johns Hopkins University. Dr. Martin is supported by the Pollin Cardiovascular Prevention Fellowship, as well as the Marie-Josée and Henry R. Kravis endowed fellowship.

In addition to Martin and Jones, other researchers on the study were: Michael J. Blaha, Mohamed B. Elshazly, Peter O. Kwiterovich and Roger S. Blumenthal from the Johns Hopkins University School of Medicine, and Peter P. Toth from the University of Illinois College of Medicine at Peoria.

Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 35 Johns Hopkins Community Physicians sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report. For more information about Johns Hopkins Medicine, its research, education and clinical programs, and for the latest health, science and research news, visit http://www.hopkinsmedicine.org.

Media Contacts:

Ellen Beth Levitt, eblevitt@jhmi.edu, 410-955-5307 or 410-598-4711 (cell)

Helen Jones, hjones49@jhmi.edu, 410-502-9422

(Note: Dr. Martin and his co-authors will be at the American Heart Association Scientific Sessions in Dallas for in-person interviews).

Ellen Beth Levitt | EurekAlert!
Further information:
http://www.jhmi.edu
http://www.hopkinsmedicine.org

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>